All In Biotech

Drug Trial Radar · NCT04628936

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis

Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Nov 4, 2020

Primary completion

Mar 10, 2023

Study completion Jun 12, 2023

Sponsor

Lead sponsor
Kezar Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM) who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.

Conditions

  • Polymyositis
  • Dermatomyositis

Interventions

  • KZR-616Drug

    Subcutaneous 30 mg for 1 week, then 45 mg weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Total Improvement Score (TIS) at OLE Week 48Time frame: 48 weeks

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • KZR Research Site

    Beverly Hills, California

  • KZR Research Site

    Orange, California

  • KZR Research Site

    Miami, Florida

  • KZR Research Site

    Kansas City, Kansas

  • KZR Research Site

    Baltimore, Maryland

  • KZR Research Site

    Ann Arbor, Michigan

  • KZR Research Site

    Duncansville, Pennsylvania

  • KZR Research Site

    Pittsburgh, Pennsylvania

  • KZR Research Site

    Austin, Texas

  • KZR Research Site

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.